Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents

Hideki Horibe; Shotaro Kawamura; Noriko Kodama; Kaori Nakagawa; Yoshihiro Murata; Hideki Kawai; Yuhki Shimizu; Masayoshi Koyasu; Kenji Takemoto; Makoto Nonogawa; Masato Watarai

Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents

Hideki Horibe, Shotaro Kawamura, Noriko Kodama, Kaori Nakagawa, Yoshihiro Murata, Hideki Kawai, Yuhki Shimizu, Masayoshi Koyasu, Kenji Takemoto, Makoto Nonogawa, Masato Watarai

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The purpose of this study was to estimate the clinical outcomes of primary stenting for acute coronary syndrome (ACS) based on the selective use of sirolimus-eluting stents (SESs). Methods: We retrospectively estimated a consecutive 197 patients with ACS who were treated with SESs or bare metal stents (BMSs) from January 2005 to April 2006. In this period, we selectively implanted SESs for small vessel or long lesion in ACS. During the follow-up period (mean 14.5±8.3 months), major adverse cardiac events (MACE) (death, recurrent myocardial infarction [re-Mi], target lesion revascularization [TLR] and stent thrombosis [ST]) were evaluated. The incidence of MACE at one year was analyzed, comparing between the SES group (44 patients) and the BMS group (153 patients). Results: During the follow up period, there were 5 deaths. 4 re-MIs, 18 TLRs and 4 STs. The incidence of MACE at one year was 11.3%, but there was no significant difference between both groups (SES group 4.8% vs. BMS group 13.1%). Conclusion: Clinical outcomes of primary stenting for ACS based on selective use of SESs for small vessel or long lesion were acceptable.

Original language	English
Pages (from-to)	13-20
Number of pages	8
Journal	Japanese Journal of Interventional Cardiology
Volume	24
Issue number	1
Publication status	Published - 2009
Externally published	Yes

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Cite this

@article{a7e678bafde247b48039c2f7b45f5c92,

title = "Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents",

abstract = "The purpose of this study was to estimate the clinical outcomes of primary stenting for acute coronary syndrome (ACS) based on the selective use of sirolimus-eluting stents (SESs). Methods: We retrospectively estimated a consecutive 197 patients with ACS who were treated with SESs or bare metal stents (BMSs) from January 2005 to April 2006. In this period, we selectively implanted SESs for small vessel or long lesion in ACS. During the follow-up period (mean 14.5±8.3 months), major adverse cardiac events (MACE) (death, recurrent myocardial infarction [re-Mi], target lesion revascularization [TLR] and stent thrombosis [ST]) were evaluated. The incidence of MACE at one year was analyzed, comparing between the SES group (44 patients) and the BMS group (153 patients). Results: During the follow up period, there were 5 deaths. 4 re-MIs, 18 TLRs and 4 STs. The incidence of MACE at one year was 11.3%, but there was no significant difference between both groups (SES group 4.8% vs. BMS group 13.1%). Conclusion: Clinical outcomes of primary stenting for ACS based on selective use of SESs for small vessel or long lesion were acceptable.",

author = "Hideki Horibe and Shotaro Kawamura and Noriko Kodama and Kaori Nakagawa and Yoshihiro Murata and Hideki Kawai and Yuhki Shimizu and Masayoshi Koyasu and Kenji Takemoto and Makoto Nonogawa and Masato Watarai",

year = "2009",

language = "English",

volume = "24",

pages = "13--20",

journal = "Japanese Journal of Interventional Cardiology",

issn = "0914-8922",

publisher = "Japanese Society of Interventional Cardiology",

number = "1",

}

TY - JOUR

T1 - Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents

AU - Horibe, Hideki

AU - Kawamura, Shotaro

AU - Kodama, Noriko

AU - Nakagawa, Kaori

AU - Murata, Yoshihiro

AU - Kawai, Hideki

AU - Shimizu, Yuhki

AU - Koyasu, Masayoshi

AU - Takemoto, Kenji

AU - Nonogawa, Makoto

AU - Watarai, Masato

PY - 2009

Y1 - 2009

N2 - The purpose of this study was to estimate the clinical outcomes of primary stenting for acute coronary syndrome (ACS) based on the selective use of sirolimus-eluting stents (SESs). Methods: We retrospectively estimated a consecutive 197 patients with ACS who were treated with SESs or bare metal stents (BMSs) from January 2005 to April 2006. In this period, we selectively implanted SESs for small vessel or long lesion in ACS. During the follow-up period (mean 14.5±8.3 months), major adverse cardiac events (MACE) (death, recurrent myocardial infarction [re-Mi], target lesion revascularization [TLR] and stent thrombosis [ST]) were evaluated. The incidence of MACE at one year was analyzed, comparing between the SES group (44 patients) and the BMS group (153 patients). Results: During the follow up period, there were 5 deaths. 4 re-MIs, 18 TLRs and 4 STs. The incidence of MACE at one year was 11.3%, but there was no significant difference between both groups (SES group 4.8% vs. BMS group 13.1%). Conclusion: Clinical outcomes of primary stenting for ACS based on selective use of SESs for small vessel or long lesion were acceptable.

AB - The purpose of this study was to estimate the clinical outcomes of primary stenting for acute coronary syndrome (ACS) based on the selective use of sirolimus-eluting stents (SESs). Methods: We retrospectively estimated a consecutive 197 patients with ACS who were treated with SESs or bare metal stents (BMSs) from January 2005 to April 2006. In this period, we selectively implanted SESs for small vessel or long lesion in ACS. During the follow-up period (mean 14.5±8.3 months), major adverse cardiac events (MACE) (death, recurrent myocardial infarction [re-Mi], target lesion revascularization [TLR] and stent thrombosis [ST]) were evaluated. The incidence of MACE at one year was analyzed, comparing between the SES group (44 patients) and the BMS group (153 patients). Results: During the follow up period, there were 5 deaths. 4 re-MIs, 18 TLRs and 4 STs. The incidence of MACE at one year was 11.3%, but there was no significant difference between both groups (SES group 4.8% vs. BMS group 13.1%). Conclusion: Clinical outcomes of primary stenting for ACS based on selective use of SESs for small vessel or long lesion were acceptable.

UR - http://www.scopus.com/inward/record.url?scp=62549093185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549093185&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:62549093185

SN - 0914-8922

VL - 24

SP - 13

EP - 20

JO - Japanese Journal of Interventional Cardiology

JF - Japanese Journal of Interventional Cardiology

IS - 1

ER -

Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this